Incyte Down as FDA Extends Review Period of Jakafi for GVHD

Incyte Down as FDA Extends Review Period of Jakafi for GVHD

Source: 
Yahoo/Zacks.com
snippet: 

Shares of Incyte Corporation INCY declined 1.9% after the FDA extended the review period of the supplemental New Drug Application (sNDA) for Jakafi to treat patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids.